LEVIN Y, Kochba E, Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same?. Vaccine. 2014 Jun 12. pii: S0264-410X(14)00368-5.
The skin provides the largest immune barrier to infection and is a readily accessible site for vaccination, although intradermal (ID) injection can be challenging. The MicronJet? microneedle is a novel device that simply and consistently injects antigens very close to the skin´s dendritic cells. A dose-sparing ID injection study was conducted in 280 healthy adult volunteers using trivalent virosomal adjuvanted influenza vaccine. ID injection of 3μg using the MicronJet? was well tolerated and showed a statistically higher geometric mean fold rise than the same dose ID using a conventional needle (Mantoux technique) for the H1N1 and B strains or a 15μg intramuscular (IM) injection for the H3N2 strain. Thus, the immune response appears to partially depend on the delivery device and route of injection. The MicronJet? may allow dose-sparing, yet give a superior response in influenza vaccination and warrants further clinical evaluation.
See Also:
Latest articles in those days:
- Global pattern and determinant for interaction of seasonal influenza viruses 5 hours ago
- Spatio-temporal dynamics and drivers of highly pathogenic avian influenza H5N1 in Chile 1 days ago
- [preprint] Avian Influenza Virus Infections in Felines: A Systematic Review of Two Decades of Literature 2 days ago
- Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe 2 days ago
- Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older 2 days ago
[Go Top] [Close Window]